Nutex Health Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

NUTX$186.25-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Equity (Deficit)

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY


· · Common Stock · · Additional Paid-in · · Retained Earnings · · Noncontrolling · · Total
· Shares · Amount · Capital · (Accumulated Deficit) · Interests · Equity

Balance at January 1, 2022	3,951,944	3,952	$12,331,731	$102,315,623	$76,929,704	$191,581,010
Reverse acquisition with Clinigence	339,741	340	436,499,926	-	194,747	436,695,013
Deconsolidation of Real Estate Entities	-	-	-	(6,466,946)	(32,336,946)	(38,803,892)
Notes payable converted to common stock	23,163	23	5,385,349	-	-	5,385,372
Common stock issued for exercise of warrants	14,315	14	4,119,127	-	-	4,119,141
Common stock issued for exercise of options	2,080	2	644,972	-	-	644,974
Rescission of warrant exercise	(5,460)	(5)	(26,386)	-	-	(26,391)
Equity financing agreement Lincoln Park Capital Fund, LLC	9,042	9	(9)	-	-	-
Stock-based compensation	-	-	189,581	-	-	189,581
Contributions	-	-	-	-	4,513,867	4,513,867
Distributions	-	-	-	(34,354,156)	(16,877,501)	(51,231,657)
Net loss	-	-	-	(424,780,446)	(7,959,172)	(432,739,618)
Balance at December 31, 2022	4,334,825	$4,335	$459,144,291	$(363,285,925)	$24,464,699	$120,327,400
Deconsolidation of Real Estate Entities	-	-	-	-	(4,258,133)	(4,258,133)
Common stock issued for exercise of warrants	8,456	8	(8)	-	-	-
Common stock issued to Apollo Medical Holding Inc.	6,667	7	1,899,993	-	-	1,900,000
Common stock issued for Employee Stock Purchase Plan	515	1	14,287	-	-	14,288
Common stock issued for acquisition	16,943	17	905,217	-	-	905,234
Debt conversion to common stock	142,384	142	6,217,595	-	-	6,217,737
Stock-based compensation	1,409	1	935,966	-	-	935,967
Warrants issued with convertible debt	-	-	1,403,877	-	-	1,403,877
Contributions	-	-	-	-	298,032	298,032
Distributions	-	-	-	-	(5,214,581)	(5,214,581)
Net income (loss)	-	-	-	(45,786,614)	2,362,899	(43,423,715)
Balance at December 31, 2023	4,511,199	$4,511	$470,521,218	$(409,072,539)	$17,652,916	$79,106,106

(Continued)

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY


· · Common Stock · · Additional Paid-in · · Retained Earnings · · Noncontrolling · · Total
· Shares · Amount · Capital · (Accumulated Deficit) · Interests · Equity

Balance at December 31, 2023	4,511,199	-	4,511	$470,521,218	$(409,072,539)	$17,652,916	$79,106,106
Common stock issuance for Securities Purchase Agreement	444,444		444	1,540,499	-	-	1,540,943
Warrant exercises	444,445		444	11,643,421	-	-	11,643,865
Common stock received in sale of business	(5,060)		(5)	(30,245)	-	-	(30,250)
Common stock issued for Employee Stock Purchase Plan	8,405		9	85,482	-	-	85,491
Common stock issued for acquisition	64,746		65	406,093	-	-	406,158
Debt conversion to common stock	11,824		12	320,676	-	-	320,688
Vesting of Restricted Stock Units	1,298		1	(1)	-	-	-
Reverse stock split adjustment	3,116		3	(3)	-	-	-
Stock-based compensation	27,035		27	16,631,871	-	-	16,631,898
Contributions	-		-	2,113,598	-	1,239,425	3,353,023
Distributions	-		-	-	-	(6,437,966)	(6,437,966)
Net income	-		-	-	52,179,168	43,092,753	95,271,921
Balance at December 31, 2024	5,511,452		$5,511	$503,232,609	$(356,893,371)	$55,547,128	$201,891,877

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.